Discover how this diabetes drug is revolutionizing heart health. Learn about its surprising benefits in reducing cardiovascular risks and mortality.

Compounding pharmacies producing cheaper semaglutide products have been given notice they will soon have to stop, as the drug is no longer on the FDA shortage list.

Semaglutide injections, which have become a popular treatment option for weight loss as well as Type 2 diabetes, have been considered to be in a shortage since 2022. This could affect Hims & Hers, ...

Shares of Hims & Hers Health (NYSE: HIMS) are falling on Friday. The company's stock lost 23.2% as of 1 p.m. ET and lost as much as 26.1% earlier in the day. The move comes as the S&P 500 lost 1% and ...

The FDA has now resolved the shortages of Novo Nordisk and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...

The cybersecurity lead for VA.gov was fired last week. He tells WIRED that the Veterans Affairs digital hub will be more ...

The ruling shows Novo Nordisk’s confidence that the supply of semaglutide will be stable for now.